A new anti-tumour treatment is one step closer to the clinic thanks to a new collaboration between In3Bio and 3P Biopharmaceuticals
3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has been chosen by In3Bio, the UK based Biotech company, to collaborate in the development of a novel anti-tumour treatment
3P Biopharmaceuticals and In3Bio began their partnership in early 2019 with 3P Biopharmaceuticals being selected to be responsible for technology transfer, process development, analytical methods development, scale-up and cGMP production for clinical studies.
In3Bio’s candidate molecule is IN02, a bi-specific biological molecule that was identified through designing fusions of molecules with high binding potential for targeting growth factors.
The technology employed by In3Bio produces new molecules specific to one or multiple growth factors at the same time. In this way, these new candidates have demonstrated a wide potential in the treatment of different cancer indications using established preclinical models, opening the door for developing effective anti-tumour therapy.
As 3P Biopharmaceuticals CEO Dámaso Molero explains, “it is an honour to help develop an anti-cancer treatment and do our best in the field of oncology with the hope of ultimately contributing to a positive effect on society“. Besides, Molero added “this innovative project strengthens the experience of 3P Biopharmaceuticals to develop complex therapeutic products applied to health and places us among the most competitive CDMOs in Europe.”
Erik D’Hondt, CEO/CSO at In3Bio, added “We at IN3BIO are pleased to cooperate with 3P Biopharmaceuticals, a CDMO with solid and broad experience to support IN3BIO for preparing Clinical batch of a chimeric biological molecule to be used in the clinic”.
According to the World Health Organization (WHO), cancer is the second leading cause of death worldwide and was responsible for an estimated 9.6 million deaths in 2018. Globally, about 1 in 6 deaths is due to cancer.
Therefore, this development represents an important advance for oncological treatments, which are critically needed given the increasing rates in cancer.
Through this collaboration, 3P Biopharmaceuticals once again demonstrates its capacity to carry out processes and manufacturing for molecules developed within diverse therapeutic applications.
